Zidovudine

證據等級: L5

預測適應症: 6 個

Note before the report: This evidence pack contains 6 TxGNN-predicted indications for zidovudine with widely varying evidence quality (from feline/monkey animal-model literature to a genuine human RCT base). Per the Evidence Level rules, only AIDS-related complex (ARC) clears L1 with an actionable "Proceed with Guardrails" call — the others are explicitly scored Hold/L4–L5 or lack real clinical relevance to humans (e.g., feline AIDS, SIV in macaques). I built the report around ARC as the primary candidate and summarized the rest as screened-and-held, rather than mechanically using rank #1 (feline AIDS), which would produce a clinically meaningless report.

One-Sentence Summary

Zidovudine (AZT) was the first antiretroviral drug ever approved, originally developed to suppress HIV replication in patients with symptomatic HIV infection. Among six indications flagged by the TxGNN model for this drug, AIDS-Related Complex (ARC) is the only one backed by substantial human clinical evidence, with 50 clinical trials and 10+ publications — including the landmark 1987 NEJM placebo-controlled trial — supporting its use in this early symptomatic stage of HIV disease.

Quick Overview

Item	Content
Original Indication	HIV infection / AIDS (zidovudine's originally approved indication; the regulatory license text was not available in this evidence pack)
Predicted New Indication	AIDS-Related Complex (ARC)
TxGNN Prediction Score	99.19%
Evidence Level	L1
Germany Market Status	未上市 (Not Marketed)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed structured mechanism-of-action data is not available in this evidence pack. Based on established pharmacology, zidovudine is a thymidine-analogue nucleoside reverse transcriptase inhibitor (NRTI): after intracellular phosphorylation to its triphosphate form, it competitively inhibits HIV reverse transcriptase and causes DNA chain termination, blocking viral replication.

AIDS-Related Complex is not a distinct disease from HIV infection — it is the historical clinical staging term (pre-1993 CDC classification) for symptomatic but not yet AIDS-defining HIV disease. Zidovudine's original approval already covered this disease stage; the TxGNN "prediction" here largely re-identifies the drug's own founding indication rather than a novel repurposing target. This is reflected in the evidence pack's own rationale note: "this is not strict repurposing but a continuation of the historically approved indication."

The mechanistic applicability is therefore self-evident — the same reverse-transcriptase-inhibition mechanism that defines zidovudine's approved use in HIV/AIDS directly extends to ARC, a milder stage of the same underlying infection.

Other TxGNN candidates screened and held: The model also flagged feline acquired immunodeficiency syndrome and simian immunodeficiency virus infection (both non-human veterinary/primate model diseases used only in translational AZT research, not independent human indications, L4–L5, Hold), an unrelated rare neurodevelopmental disorder and "obsolete familial combined hyperlipidemia" (no supporting literature; the latter contradicts known NRTI-associated mitochondrial toxicity/lipodystrophy, judged a likely false positive), and congenital HIV (evidence pending classification). None of these met the bar for further action at this time.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00001011	Phase 3	Completed	538	Safety and usefulness of AZT specifically in patients with early symptomatic HIV/early ARC
NCT00002334	Phase 3	Completed	3000	AZT alone vs. AZT+ddC vs. AZT+saquinavir vs. triple combination in AZT-naive patients
NCT00000736	Phase 3	Completed	3200	AZT delays onset of AIDS/ARC in asymptomatic HIV-infected individuals; dose-comparison for toxicity
NCT00001022	Phase 3	Completed	1200	AZT vs. AZT+ddI vs. AZT+ddC in delaying AIDS-related conditions
NCT00000625	Phase 2	Completed	2100	AZT monotherapy vs. combination nucleoside analogs in patients with CD4 200–500/mm³
NCT00000751	Phase 3	Completed	1600	HIVIG plus intrapartum/newborn AZT for prevention of mother-to-child HIV transmission
NCT00000637	Phase 3	Completed	819	AZT vs. ddI vs. AZT+ddI in symptomatic HIV-infected children
NCT00002035	RCT	Completed	300	Double-blind comparison of continued AZT vs. ddI in patients failing AZT (Grade A relevance)
NCT00002290	RCT	Completed	N/A	Multi-center double-blind trial of AZT + acyclovir vs. AZT alone in early symptomatic HIV (Grade A)
NCT00001104	Phase 3	Completed	538	Placebo-controlled trial of AZT in HIV-infected hemophilic patients

Literature Evidence

PMID	Year	Type	Journal	Key Findings
3299089	1987	RCT	New England Journal of Medicine	Landmark double-blind, placebo-controlled trial (N=282) establishing AZT efficacy in AIDS/advanced ARC
2677429	1989	RCT	JAMA	Long-term AZT therapy in 229 AIDS/ARC patients; survival benefit maintained over ~21 months
1777174	1991	RCT	AIDS	European-Australian trial (N=199): AZT ± acyclovir for ARC; no added benefit from acyclovir
8096703	1993	RCT	AIDS	Double-blind randomized trial confirming AZT ± acyclovir efficacy/safety in AIDS and ARC
2159707	1990	RCT	American Journal of Medicine	ACTG Phase I/II combination AZT + ddC in AIDS/advanced ARC
2159705	1990	RCT	American Journal of Medicine	Alternating/intermittent AZT + ddC dosing regimens to reduce toxicity in AIDS/ARC
2191113	1990	RCT	J Acquir Immune Defic Syndr	Quality-of-life substudy of placebo-controlled AZT trial; improved Karnofsky/QWB scores vs. placebo
3059187	1988	RCT	New England Journal of Medicine	Double-blind, placebo-controlled trial (N=281) assessing neuropsychological outcomes of AZT in AIDS/ARC
1894937	1991	Clinical study	Journal of Infectious Diseases	AZT-treated AIDS/ARC patients show improved antibody response to pneumococcal vaccine
2224694	1990	Review	CMAJ	Comprehensive review of AZT efficacy across HIV disease stages, including ARC

Germany Market Information

No marketing authorizations are on record for zidovudine in this evidence pack — market status is 未上市 (Not Marketed), with 0 registered licenses. No product/dosage-form/indication-text data is available to tabulate.

Safety Considerations

Please refer to the package insert for safety information. (Structured key warnings, contraindications, and drug-interaction data were not available in this evidence pack; note, however, that the literature evidence above documents zidovudine's well-known hematologic toxicity — see PMID 2224694 and related tolerability reports — which should be factored into any monitoring plan.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale:

ARC is supported by L1-level evidence — multiple completed Phase 3 RCTs, including the foundational 1987 NEJM trial — but this reflects zidovudine's original approved use rather than a genuinely novel repurposing opportunity, and the drug is not currently marketed in this jurisdiction.

To proceed, the following is needed:

Confirm whether "new indication" framing is appropriate given ARC is a historical HIV disease stage already within zidovudine's original label
TFDA/BfArM package insert data to complete the S1 safety review (currently a blocking data gap per this pack's data_gaps)
Structured DrugBank MOA and DDI data (also flagged as a data gap)
Regulatory/licensing pathway assessment given current "Not Marketed" status and 0 authorizations
Hematologic monitoring plan (CBC with differential) given AZT's known myelosuppressive profile, since it would now only be used within combination ART, not as monotherapy

Not pursued further at this time (Hold): feline immunodeficiency syndrome, SIV infection (non-human models only), the unrelated rare neurodevelopmental disorder, "obsolete familial combined hyperlipidemia" (likely false positive, contradicts known NRTI lipid/mitochondrial toxicity), and congenital HIV (evidence classification incomplete).

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.